Oncternal Therapeutics EBIT

Oncternal Therapeutics (ONCT) currently reports a EBIT of $-54M as of September 2024. That compares with $-44M in the prior-year period — down 23.2% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Oncternal Therapeutics's EBIT history and peer comparisons.

Oncternal Therapeutics's EBIT decreased from $-44M to $-54M — a 23.2% year-over-year decrease (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Oncternal Therapeutics's EBIT of $-54M is lower than the Healthcare sector average of $22B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Oncternal Therapeutics reported $-54M in EBIT as of September 2024. That compares with $-44M in the prior-year period — down 23.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-54M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Oncternal Therapeutics, and consider following ONCT for alerts when major investors trade the stock.